Selective serotonin reuptake inhibitors (SSRIs), the most widely used drugs for the treatment of depression, have been reported to reduce bone formation and increase the risk of bone fracture. Since osseointegration is influenced by bone metabolism, this study aimed to investigate the association between SSRIs and the risk of failures in osseointegrated implants. This retrospective cohort study was conducted on patients treated with dental implants from January 2007 to January 2013. A total of 916 dental implants in 490 patients (94 implants on 51 patients using SSRIs) were used to estimate the risk of failure associated with the use of SSRIs. Data analysis involved Cox proportional hazards, generalized estimating equation models, multilevel mixed effects parametric survival analysis, and Kaplan-Meier analysis. After 3 to 67 mo of follow-up, 38 dental implants failed and 784 succeeded in the nonusers group, while 10 failed and 84 succeeded in the SSRI-users group. The main limitation of this retrospective study was that drug compliance dose and treatment period could not be acquired from the files of the patients. The primary outcome was that compared with nonusers of SSRIs, SSRI usage was associated with an increased risk of dental implants failure (hazard ratio, 6.28; 95% confidence interval, 1.25-31.61; p = .03). The failure rates were 4.6% for SSRI nonusers and 10.6% for SSRI users. The secondary outcomes were that small implant diameters (≤4 mm; p = .02) and smoking habits (p = .01) also seemed to be associated with higher risk of implant failure. Our findings indicate that treatment with SSRIs is associated with an increased failure risk of osseointegrated implants, which might suggest a careful surgical treatment planning for SSRI users.
SSRIs and Implant Failure
Osseointegration of implants is highly dependent on the quality of the recipient bone (Wong et al., 1995) , and since SSRIs seem to have a negative effect on bone formation (Battaglino et al., 2004; Gustafsson et al., 2006; Diem et al., 2007) , we hypothesize that SSRI treatment might have a negative effect on titanium implant osseointegration and survival rate. Given the large portion of the population taking SSRIs, and the increased number of surgeries using osseointegated implants, it is vital to investigate whether SSRI treatment can affect osseointegated implant survival rate. In order to test our hypothesis, a cohort study was carried out on patients treated with one type of osseointegrated medical devices, titanium dental implants, to investigate whether the use of SSRIs is associated with higher risk of titanium implant failure.
MAtErIAls & MEthODs patients and Data sources
Approval (12-321 GEN) was obtained from the Ethical Committee for Clinical Trials of McGill University to carry out a retrospective cohort study in the dental clinic East Coast Oral Surgery (Moncton, Canada). Written informed consent was granted from all subjects. Our study is a human observational study and has conformed to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines.
Records of patients with dental osseointegrated prosthesis for this retrospective cohort study were identified in the clinic database, and the original hard copy files were retrieved for manual examination. The overall study period was 6 yr, between January 1, 2007, and September 8, 2013 . Preoperative patient information, including medication, habits, and behavioral factors, was selfreported through a standardized questionnaire that was filled prior to the surgical intervention. Patients were excluded if they had a severe systemic disease (American Society of Anaesthesiology III or IV), were pregnant, or had a medical disorder known to substantially affect bone metabolism, such as osteoporosis, osteomalacia, Paget's disease, vitamin D deficiency, hyperthyroidism, cancer (excluding nonmelanoma skin cancer), or alcoholism, as were those on corticosteroids, antiepileptic drugs, antihypertensive drugs, proton pump inhibitors, or bisphosphonates (Tamimi et al., 2012) . Smoking habit was considered in our analysis; subjects who smoked more than 10 cigarettes per day were defined as smokers (Tonetti et al., 1995) .
ssrI Medication Definition
SSRI usage was defined as filling a prescription for SSRIs at the time of implant placement (citalopram, dapoxetine, escitalopram, fluoxetine, fluvoxamine, indalpine, paroxetine, sertraline, venlafaxine, and zimelidine; Diem et al., 2007) .
surgical protocol and postoperative treatment
In patients with sufficient native bone, implant (Nobel Biocare) surgery was performed under local anaesthesia, with or without intravenous sedation, according to the manufacturer's recommended protocol (Finkemeier, 2002) . In cases with inadequate bone volume for implant placement, bone augmentation (i.e., lateral bone grafting, sinus lifting) was performed 6 mo prior to implant placement via a mixture of autogenous and allogenic bone substitutes (allogeneic bone, Straumann, Andover, MA, USA; Finkemeier, 2002) .
The use of antibiotics in implant dentistry is controversial, so postoperatively, patients were instructed to rinse 4 times per day for a period of 7 d with 0.2% chlorhexidine solution (Peridex, Periogard, Allentown, PA, USA) and to follow a soft diet. They also received prophylactically a prescription of antibiotics for a period of 7 d (amoxicillin, 500 mg, orally, 3 times per day [GlaxoSmithKline, Middlesex, UK], or clindamycin, 300 mg, orally, 4 times per day [Sandoz, Boucherville, Canada] Patients were seen for follow-up examinations 10 d after surgery; all sutures were removed; and hygiene instructions were reinforced. Before delivery of the final implant-supported prosthesis, osseointegration was evaluated clinically by assessing vertical, lateral, and rotational signs of mobility. Implants with at least one of the following complications were defined as failures: pain on function; mobility; radiographic bone loss equivalent to one-half of the implant length; uncontrolled exudate; or implant no longer in mouth (Misch et al., 2008) .
study Outcomes and Follow-up
The primary study endpoint was a binary dental implants outcome, comprising successful implants and failed implants. For either outcome, we followed patients until they experienced dental implant failure, died, or were censored for losing the track or reaching the end of the study period, whatever came first. The following parameters were retrieved from the patients' files and standardized questionnaires: patient age, sex, implant dimensions, bone augmentation, smoking habit, physical condition, medicine undertaken, and follow-up time.
sample size calculation and statistical Analysis
This cohort study was designed to examine the association between dental implant failure and SSRI treatment along with other factors. Sample size calculation based on Cohen's F test indicated that a minimum of 645 implants was required to achieve a power of 0.8 at an effect size (f 2 ) of 0.25 and a probability level of 0.05 with 8 covariates (Kemp, 2003) . Accordingly, differences were considered of no clinical relevance if <1.1% based on Cohen's F test with a 25% standard deviations difference between the 2 groups' means (Pjetursson et al., 2012) .
Comparison between SSRI users and nonusers in terms of demographic systemic conditions and other factors, as well as the healing period calculation, was done through the chi-square test. Cox proportional hazards model was performed to assess the association between potential risk factors, including SSRI usage, and dental implant failure rate, adjusting for potential confounders factors. In addition, we used generalized estimating equation (GEE) models and multilevel mixed effects parametric survival analysis (Stephenson et al., 2010) to account for cluster effects of multiple implants when placed and evaluated in a single patient (repeated observations; Zeger and Liang, 1986; Stephenson et al., 2010) .
Analyses were adjusted to the following potential confounders: sex, age, implant diameter, implant length, bone augmentation, smoking habit. These covariates were selected because of their associations with bone status or dental implant survival rate and have been controlled for in studies of similar design (Verdel et al., 2010) . Statistical analysis was performed with the software SPSS 19.0 and STATA13 for Windows. The results were considered statistically significant if the corresponding p value was < .05. Post hoc power calculation was done with Cohen's F test. Kaplan-Meier survival curves were plotted for the primary outcome "dental implant failure."
rEsults
During the study period between 2007 and 2013, 42 implants in 23 patients were excluded for bone-related diseases and medications ( Fig. 1) . In sum, the 490 patients who met our inclusion consisted of 292 women and 198 men, with ages spanning 17 to 93 yr, averaging 56.4 ± 13.7. A total of 916 dental implants were placed in the included patients, out of which 94 were placed in SSRI users whereas 822 were placed in SSRI nonusers. Also, 436 implants were placed in nonsmokers, whereas 54 were placed in smokers. Implants had diameters ranging from 3.0 to 5.5 mm, lengths ranging from 7.0 to 42.0 mm, and torque at insertion from 10 to 65 N˙cm (Appendix Table 2 ). The healing period for all implants was ranging from 0 to 8 mo (5.1 ± 1.6). Other relevant information is shown in Appendix Tables 1 and 3 .
During the entire observation period, 868 implants survived and 48 failed. The failure rates were 4.6% for SSRI nonusers and 10.6% SSRI users. SSRI users and nonusers were comparable in terms of age, sex, bone augmentation, smoking habit, implant diameter, implant length, implant torque, and follow-up period (Table 1) . Risk analysis confirmed our hypothesis by revealing that SSRI treatment (p = .03) was associated with an increased risk of implant failure (Table 2) . Also, smoking habit (p = .01) and small (≤4 mm) implant diameter (p = .02) were associated with an increased risk of implant failure (Table 3) . Multilevel survival analysis adjusted for potential confounding factors is shown in Table 1 and 2. Patient's age, sex, bone augmentation, follow-up period, implant length, and torque had no significant association with implant survival rate (Table 3) . The post hoc power was 0.93. Kaplan-Meier survival curves for dental implant failure in terms of SSRI use, bone augmentation, smoking habit, and implant diameter are shown in Figure 2 . 
DIscussIOn
Our hypothesis was confirmed by the present study, showing through a multivariate analysis that SSRI usage, as well as other factors, increases the risk of osseointegrated dental implant failure. Each of these factors is discussed in detail.
ssrIs and Dental Implant Failure
Our study focused on the possible association of SSRI treatment with increased dental implant failure. In Table 2 , we show that SSRIs have a significant association with higher risk of dental implant failure. Despite the fact that there were no significant differences between the group of SSRI users and nonusers in terms of systemic and demographic conditions (Table 1) , SSRI users were more susceptible (hazard ratio, 6.28; 95% confidence interval, 1.25-31.61) to implant failures than nonusers. Osseointegrated implant failure is usually caused by failed osseointegration, peri-implantitis, mechanical overloading (Esposito et al., 1998) , or a combination of these factors (Tonetti and Schmid, 1994) . Early failures, occurring weeks to a few months after implant placement (Tonetti and Schmid, 1994) , often result from impaired healing (Esposito et al., 1998) , implant contamination, or lack of mechanical stability (Tonetti and Schmid, 1994) . Late failures are frequently caused by periimplantitis (plaque-induced progressive marginal bone loss) mainly occurring after two-year follow-up (Charalampakis et al., 2012) . The failures caused by mechanical overloading usually occur after the loading time of 4 and 6 mo (Esposito et al., 1998) . In our study, the stratification of the follow-up period in Kaplan-Maier curves showed that failures occurred mostly between 4 and 14 mo (8 failed cases out of 10) after implant placement. Implants placed in SSRI users had favorable primary mechanical stability (torque: 29.6 ± 8.8 N˙cm), acceptable bone quality and quantity, appropriate implant dimensions, and good early healing (all implants were loaded; Table 1 ). Therefore, the main reason causing implant failure by SSRIs was probably associated with problems in the mechanical loading of the implants. This is in agreement with previous in vivo studies demonstrating that serotonin plays an important role in the anabolic response of bone to mechanical loading (Sibilia et al., 2013) . This study indicates that SSRIs might cause bone mass loss by inhibiting the bone-remodeling processes triggered by mechanical loading. Accordingly, SSRIs might also be impairing bone remodeling around functional implants, although this hypothesis will require further mechanistic experiments to be confirmed.
Inappropriate response to mechanical loading can be the possible cause of "the after-loading failures." Future studies are needed to confirm the hypothesis. However, the effect of SSRIs on the risk of implants failures in our study can to some extent lead to careful surgical planning in SSRI users.
bone Augmentation and Dental Implant Failure
In our study, bone augmentation seemed to be associated with higher dental implant failure in GEE analysis, but the association was not significant on the basis of multilevel mixed effects parametric survival analysis in STATA. Bone augmentation is essential for placement of implants when bone volume is insufficient. However, previous studies (Yamazaki et al., 2012) indicated that higher implant survival rate can be expected when there is no need for bone regeneration procedures. The negative impact might indicate that the quality and quantity of regenerated bone are often deficient (Yamazaki et al., 2012) . Moreover, bone surgeries may require more maintenance of bone integrity and more firm immobilization after surgeries (Yamazaki et al., 2012) .
smoking habit and Dental Implant Failure
In this study, we observed a significant increased risk of dental implant failure associated with smoking habits. This was in agreement with previous studies recognizing a higher rate of dental implant failure in smokers (odds ratios ranging from 3.6 to 4.6; Alsaadi et al., 2008) , probably because smoking impairs bone healing after dental implant surgical treatment. The adverse effect during the early stage of osseointegration may be explained by the influence of smoking on the wound-healing process (Alsaadi et al., 2008) through a direct toxic effect (Krall and Dawson-Hughes, 1991) on the bone around implants.
Smoking, especially nicotine, impairs new bone formation, reduces calcium absorption, and decreases bone mineral density transiently (Riebel et al., 1995) .
Implant Dimensions and Dental Implant Failure
We demonstrated that smaller implant diameters were associated with higher risk of implant failure, which was confirmed by other studies (Davarpanah et al., 2000) . The use of narrowdiameter implants has been proposed to avoid bone augmentation procedures and reduce surgical complexity (Davarpanah et al., 2000) . However, they have less surface area for interaction and anchorage, which may lead to insufficient bone integration, as well as unfavorable distribution of biomechanical forces, causing reduced resistance to fracture (Davarpanah et al., 2000) . In our study, we did not observe a significant association between short implant length and increased failure. The implant length may be a factor in survival (Porter and von Fraunhofer, 2004) , but in our study, it does not appear to be as critical as SSRI treatment, bone quality, smoking habits, and implant diameters. 
superiority and limitations
To avoid bias, we had comparable control and experimental groups (Table 1) with sufficient sample size. We performed a comprehensive statistical analysis adjusted to multiple confounders with sufficient power and used GEE models and multilevel mixed effects parametric survival analysis to solve data cluster. Furthermore, the surgeries for all included patients were carried out by a single surgeon, avoiding most of the personal bias and operation variances. However, there were still several factors that could not be assessed in the study. Because of the lack of detailed information, we were not able to adjust to the degree of depression (Verdel et al., 2010) , which might be a predictor for implant success rate. Within the limit of our knowledge, there is no evidence in the literature on whether depression is a risk factor for implant failure or oral complications. Lack of information about oral hygiene as dental implant maintenance was one of our limitations (Porter and von Fraunhofer, 2004) . Moreover, drug compliance dose and treatment period could not be acquired from the files of the patients. Further studies investigating the dose-effect relationship and the influence of the treatment duration should be carried out to analyze this phenomenon in more depth. Moreover, the aspect of dose-relevant effects on bone metabolism could be of interest for prospective investigations. Randomized clinical trials should also be carried out in the future to confirm our results, since there is selection bias, such as confounding by indication, missing clinical data, and the risk of underreporting data in cohort studies. Nevertheless, our study indeed, for the first time, indicated an association between SSRI treatment and higher risk of dental implant failure. Thus, this study might suggest careful surgical treatment planning for SSRI users.
cOnclusIOn
Within the limits of our study, we can conclude that SSRI treatment is associated with higher risk of osseointegrated implant failure. Implant survival rate could also be significantly influenced by other factors, such as implant diameter, bone augmentation, and smoking habits.
